Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution

ABSTRACT: Following the recent approval of both siRNA- and mRNA-based therapeutics, nucleic acid therapies are considered a game changer in medicine. Their envisioned widespread use for many therapeutic applications with an array of cellular target sites means that various administration routes will be employed. Concerns exist regarding adverse reactions against the lipid nanoparticles (LNPs) used for mRNA delivery, as PEG coatings on nanoparticles can induce severe antibody-mediated immune reactions, potentially being boosted by the inherently immunogenic nucleic acid cargo. While exhaustive information is available on how physicochemical features of nanoparticles affects immunogenicity, it remains unexplored how the fundamental choice of administration route regulates anti-particle immunity. Here,

SUBMITTER: Munter R 

PROVIDER: S-EPMC10220314 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature